Enhancement of amphetamine action after interruption of ascending serotonergic pathways.
D000818:Animals; D001522:Behavior, Animal / Q000187:drug effects; D001679:Biogenic Amines / Q000032:analysis; D001835:Body Weight / Q000187:drug effects; D001921:Brain / Q000033:anatomy & histology / Q000502:physiology; D001923:Brain Chemistry; D002746:Chlorpromazine / Q000494:pharmacology; D003913:Dextroamphetamine / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D004298:Dopamine / Q000378:metabolism; D004327:Drinking Behavior / Q000187:drug effects; D008297:Male; D009474:Neurons / Q000502:physiology*; D009638:Norepinephrine / Q000378:metabolism; D051381:Rats; D012055:Reinforcement Schedule; D012201:Reward; D012701:Serotonin / Q000378:metabolism / Q000502:physiology*; D013194:Staining and Labeling; D013687:Telencephalon / Q000378:metabolism
D001679:Biogenic Amines; D012701:Serotonin; D003913:Dextroamphetamine; D002746:Chlorpromazine; D004298:Dopamine; D009638:Norepinephrine